• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011 Product Image

Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

  • Published: November 2011
  • 103 pages
  • Global Markets Direct

Sunesis Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Sunesis Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sunesis Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Sunesis Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sunesis Pharmaceuticals, Inc. - Brief Sunesis Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sunesis Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy READ MORE >



List of Tables
List of Figures
Sunesis Pharmaceuticals, Inc. Snapshot
Sunesis Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Sunesis Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Sunesis Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. – Pipeline Products Glance
Sunesis Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. – Drug Profiles
BIIB024
SNS-032
SNS-314
Vosaroxin
Vosaroxin + Cytarabine
Sunesis Pharmaceuticals, Inc. – Pipeline Analysis
Sunesis Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Sunesis Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Sunesis Pharmaceuticals, Inc. – Recent Pipeline Updates
Sunesis Pharmaceuticals, Inc. - Dormant Projects
Sunesis Pharmaceuticals, Inc. – Company Statement
Sunesis Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 26, 2011: Sunesis To Host Conference Call To Discuss Corporate Updates And VALOR Poster Presented At ASCO 2011
Feb 23, 2011: Sunesis Receives FDA Fast Track Designation For Vosaroxin In AML
Jul 20, 2011: Sunesis Announces Publication Of Phase Ib Data Of Vosaroxin In Relapsed Or Refractory Acute Leukemia
Mar 10, 2011: Sunesis Wins European Patent Covering Vosaroxin Clinical Formulation
Jun 06, 2011: Sunesis Announces Presentation Of Adaptive Study Design For Vosaroxin Phase III VALOR Trial In AML At ASCO 2011
May 05, 2011: Sunesis Announces Publication Of Nonclinical Data Demonstrating Activity Of Vosaroxin In Acute Myeloid Leukemia Blasts
May 05, 2011: Sunesis Announces Publication Of Nonclinical Data Demonstrating Activity Of Vosaroxin In Combination With Cytarabine In Acute Myeloid Leukemia Blasts
Apr 04, 2006: Sunesis Presents Data On Anti-Cancer Compound SNS-032 At American Association For Cancer Research Meeting
Aug 03, 2011: Sunesis Receives US Patent Covering Vosaroxin Use To Treat Leukemia
Financial Deals Landscape
Sunesis Pharmaceuticals, Inc., Deals Summary
Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Sunesis Pharmaceuticals Extends Research Collaboration With Johnson & Johnson
Sunesis Pharmaceuticals Extends Research Collaboration With J&JPRD
Licensing Agreements
Materia Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Biogen Idec
Equity Offering
Sunesis Pharmaceuticals Files Registration Statement For Public Offering Of Common Stock For $20 Million
Sunesis Pharmaceuticals Completes Initial Public Offering Of $42 Million
Asset Transactions
Sunesis Pharmaceuticals Sells LFA-1 Inhibitor Program To SARcode
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Sunesis Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Sunesis Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Phase III, H2 2011
Sunesis Pharmaceuticals, Inc. - Phase II, H2 2011
Sunesis Pharmaceuticals, Inc. - Phase I, H2 2011
Sunesis Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Sunesis Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Sunesis Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Sunesis Pharmaceuticals, Inc., Subsidiaries
Sunesis Pharmaceuticals, Inc., Deals Summary
Sunesis Pharmaceuticals Extends Research Collaboration With Johnson & Johnson
Sunesis Pharmaceuticals Enters Into An Agreement With Biogen Idec
Sunesis Pharmaceuticals Enters Into Research Collaboration With Merck
Sunesis Pharmaceuticals Extends Research Collaboration With J&JPRD
Materia Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Millennium Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Carmot Therapeutics
CyDex Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Enters Into Licensing Agreement With SARcode
Sunesis Pharmaceuticals Enters Into Research and License Agreement With University Of California
Sunesis Pharmaceuticals Enters Into Licensing Agreement With SARcode For LFA-1
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Bristol-Myers Squibb
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Biogen Idec
Sunesis Pharmaceuticals Files Registration Statement For Public Offering Of Common Stock For $20 Million
Sunesis Pharmaceuticals Completes Public Offering Of $15.5 Million
Sunesis Pharmaceuticals Completes First Tranche Of Private Placement For $10.7 Million
Sunesis Pharmaceuticals Completes Private Placement Of $28.5 Million
Sunesis Pharmaceuticals Completes Private Placement Of $15 Million
Sunesis Pharmaceuticals Completes Second Tranche Of Private Placement For $5 Million
Sunesis Pharmaceuticals Completes Public Offering Of $21 Million
Sunesis Pharmaceuticals Completes Private Placement Of $45 Million
Sunesis Pharmaceuticals Completes Initial Public Offering Of $42 Million
Sunesis Pharmaceuticals Sells LFA-1 Inhibitor Program To SARcode

List of Figures
Sunesis Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Sunesis Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos